Regeneron beats expectations on fourth-quarter 2018 results

6 February 2019

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) today released financial results, showing that fourth quarter 2018 revenues were $1.93 billion, an increase of 22%. Full-year revenues were $6,711 billion, up 14%.

Fourth quarter 2018 generally accepted accounting principles (GAAP) diluted earnings per share (EPS) were $7.15, and non-GAAP diluted EPS was $6.84. Full year 2018 GAAP diluted EPS was $21.29, and non-GAAP diluted EPS was $22.84.

The consensus of analysts polled by Zacks Investment Research expected fourth-quarter adjusted earnings of $5.69 per share on $1.71 billion in revenue. Regeneron’s shares rose 3.3% to $435 before the market opened.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK